Novartis disclosed seven previously unknown tumor cases among children treated with the spinal muscular atrophy gene therapy Zolgensma. Since its 2019 approval, nine tumors have been reported in treated patients; two showed evidence of a possible link to the therapy. Regulators are examining the cas